

| | | | | | |
|---|--|--|--|--|--|
| Sector: Poultry | | | | | |
| Date: 28/07/2020 | | | | | |
| <input checked="" type="checkbox"/> Meeting <input type="checkbox"/> tel <input type="checkbox"/> e-mail | | | | | |
| Participants: Olivier SALANDRE (SNGTV Veterinary Representative) Claire CHAUVIN (Anses Ploufragan) - in Skype | | | | | |
| New/ added comments post meeting | | | | | |

General remarks: The deficiency in terms of antipyretics, analgesics and local anaesthetics is detrimental to animal welfare in the poultry sector. The New Regulation will change the fixed withdrawal times applicable under the "cascade" in a number of cases: communication on changes with a significant practical impact would be helpful. (reminder: the oldest marketing authorisations are suitable for the profession insofar as the target species mentioned is "poultry". The accuracy of the species in the SPC leads to difficulties of use under the "cascade" due to the imposed withdrawal time).

| Meeting PRIORITIES | Risks | Action to be taken | Who | Deadline | Status | Comments |
|--|---|--|--|-----------------|-------------|---|
| Major: M minor: m | | | | | | |
| M | <p>OTC use on viral diseases. Risk of using aspirin or paracetamol in absence of MRL dossier on eggs and poultry.</p> <p>Acetyl salicylic acid ("aspirin"), sodium acetylsalicylate and sodium salicylate: "Do not use in animals producing milk or eggs intended for human consumption".</p> <p>For sodium salicylate, the EPMAR of 15 January 2013 (EMA/CVMP/71291/ 2012) on the extension of MRLs to turkeys specifies that <u>the active substance must not be used in animals producing eggs intended for human consumption</u>. The EPMAR of 12 December 2016 (EMA/CVMP/454104/2016) specifies that <u>there is no extrapolation possible from turkey MRLs to broilers and laying hens</u>.</p> <p>The NVR will confirm the ban on poultry use via the cascade. => Nothing in pain management in laying machines (Animal welfare problem).</p> | <p>Determination of MRL eggs (and meat if necessary) for paracetamol by industry or by a national or European body.</p> <p>(For sodium salicylate, with the MRLs defined for turkey meat, we are already at 96% of the ADI).</p> <p>* Ploufragan laboratory, if requested, can conduct studies (verification of WT) if necessary for the LMR file.</p> | <p>Industrial via SIMV</p> <p>Anses Ploufragan</p> | To be specified | | <p>According to regulation 2017/880, no extrapolation possible between unrelated species, or between tissues and eggs within the same species</p> <p>=> Need for data on metabolism and residues in poultry to obtain an MRL for eggs.</p> <p>It should be noted that the NVR will support this prohibition of use in the absence of data and ensure 5 years protection on the data submitted.</p> |
| M (but no short-term solution) | | <p>Possibility of setting up studies with possible funding from the sector in conjunction with what is done in Austria.</p> | <p>Anses Ploufragan</p> | To be completed | In progress | |
| M (multi-channel transversal priority) | <p>Animal welfare problem and societal expectations</p> | <p>* Discuss identified needs with Anses DER</p> | <p>Anses Ploufragan ANMV</p> | | | |

| | | | | | | |
|---|---|---|---|-----------------|-----------|--|
| m | Use of Colistin and Aminoglycosides against E.coli, while not absorbed by the digestive tract => inappropriate use ("disinfectant" type). | <p>* Prevention method; background study to be conducted on the epidemiology of colibacilli, vertical/horizontal contamination.</p> <p>* Biosecurity; propose actions as part of the Eco antibio 2 programme (DGAL funding)?</p> <p>* Inform about CVMP modifications on Enrofloxacin indications</p> <p>* Inform about the ability to produce autovaccines without mentioning the target strains/species (depending on interest)</p> | Sector & Anses Ploufragan Sector? ANMV MAH | 2022 | Completed | <p>Indication withdrawn since opinion of the CVMP of Feb. 2018</p> <p>Advertising is prohibited for auto-vaccines in the decree and in the future regulations. However, it may be possible to communicate about the ability to produce autovaccines without mentioning the target strains/species for which they are authorised.</p> |
| m | <p>Non-compliance of WT when using toltrazuril in standard broilers.</p> <p>"Phyto" alternatives used without an official claim and rather indications such as "contributes to the management of the risk associated with coccidia". Products used in drinking water, therefore equivalent to treatments. No rigorous efficacy studies.</p> | To be specified | MAH (Zoëtis) | To be specified | | |
| m | <p>Inappropriate and off-label use of flubendazole or fenbendazole at higher or more repeated doses</p> <p>=> impact on residues/environment?</p> | <p>* Develop metabolism data and residues in poultry to obtain MRL Praziquantel poultry eggs (and meat).</p> <p>* Plan field trials (on breeders for example) to study the efficacy of praziquantel.</p> | Industrial via SIMV Sector | To be specified | | <p>Praziquantel included in Table 1 with no MRL required for sheep (total residues < 30% ADI) and horse.</p> <p>=> Need for metabolism data and poultry residues to be provided for possible extrapolation to this species.</p> |
| m | Currently MRL enilconazole only for topical use while the product is used against aspergillosis <u>by spraying in the presence of animals.</u> | <p>* Rework the IMAVERAL file for turkeys to avoid the cascade.</p> <p>*What are the risks for the user of off-label spray use?</p> | MAH (Elanco) | | | <p>Nothing new. MRL file to be developed for Turkeys. MRL exists for cattle (total residues < 11% ADI) and horses for topical use. To be requested?</p> |
| 0 | | *What is the impact of NVR on WT parconazole to be applied to turkey (0 days in guinea fowl)? | ANMV | | Completed | Parconazole BP to be applied to turkey: with NVR, change to 1 day (0 days in guinea fowl) |
| m | | * Inform about the ability to produce autovaccines without mentioning the target strains/species (depending on interest) | Owners | To be specified | | <p>Advertising is prohibited for autovaccines in the decree and in the future regulations. On the other hand, it may be possible to communicate about the ability to produce autovaccines without mentioning the target strains/species for which they are authorised.</p> |
| m | Risk of using prohibited products (dimetridazole). ??? (Minor) risk of systematic use of macrolides. | * Do we have information on the use of dimetridazole in turkeys? | String? | | | |
| 0 | | *What is the impact of NVR on WT to be applied? | ANMV | | Completed | NVR impact on cascade may allow more favourable WTs for certain antibiotics |
| 0 | | * Information on availability of small packs of vaccines available? | ANMV | 31/07/20 | | <p>Check if marketing of the smallest packs available: COLOMBOVAC PMV (Zoëtis) - pigeons: 1 vial of 10 doses, 50 doses - unavailable ? NOBILIS PARAMYXO P201 (Intervet) - pigeons: 1 vial of 20 mL (=80 doses) IMOPEST (BI) - chickens & pigeons: 1 vial of 500 doses TUR-3 (BI) - turkeys: 150 mL vial (=500 doses)</p> |